

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

^N**Codeine Contin**[®]

Codeine Controlled Release Tablets
50 mg 100 mg 150 mg and 200 mg

Purdue Pharma Std.

Opioid Analgesic

Purdue Pharma
575 Granite Court
Pickering, ON
L1W 3W8

Date of Revision:
September 12, 2018

Submission Control No.: 216666

Codeine Contin[®] is a trademark of Purdue Pharma

TABLE OF CONTENTS

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION	3
INDICATIONS AND CLINICAL USE	3
CONTRAINDICATIONS	4
WARNINGS AND PRECAUTIONS.....	4
ADVERSE REACTIONS.....	15
DRUG INTERACTIONS	17
DOSAGE AND ADMINISTRATION	18
OVERDOSAGE.....	24
ACTION AND CLINICAL PHARMACOLOGY.....	25
STORAGE AND STABILITY	27
SPECIAL HANDLING INSTRUCTIONS	27
DOSAGE FORMS, COMPOSITION AND PACKAGING	28
PART II: SCIENTIFIC INFORMATION	30
PHARMACEUTICAL INFORMATION.....	30
CLINICAL TRIALS	32
DETAILED PHARMACOLOGY	32
MICROBIOLOGY.....	32
TOXICOLOGY	33
REFERENCES.....	34
PATIENT MEDICATION INFORMATION	36

^NCodeine Contin[®]
(codeine controlled release tablets)

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strengths	Nonmedicinal Ingredients
Oral	Controlled Release Tablets / 50 mg, 100 mg, 150 mg and 200 mg	D&C Yellow No. 10 Aluminum Lake (100 mg), FD&C Blue No. 2 Aluminum Lake (50 mg), FD&C Red No. 40 Aluminum Lake (150 mg), FD&C Yellow No. 6 Aluminum Lake (100 mg, 150 mg and 200 mg), hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, polyethylene glycol, stearyl alcohol, talc and titanium dioxide

INDICATIONS AND CLINICAL USE

Adults:

Codeine Contin[®] (codeine controlled release tablets) is indicated for the relief of mild to moderate pain requiring the prolonged use of an opioid analgesic preparation.

Codeine Contin is not indicated as an as-needed (prn) analgesic

Geriatrics (> 65 years of age):

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, and titrated slowly, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease or other drug therapy (see **ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Geriatrics**).

Pediatrics (< 18 years of age):

Regardless of the clinical setting, codeine, including **Codeine Contin**, should not be used in children below the age of 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine (see **WARNINGS AND PRECAUTIONS, Special Populations and Conditions, Pediatrics; also, DOSAGE AND ADMINISTRATION**).

Codeine Contin has not been studied in the pediatric population, therefore the use of Codeine Contin is not recommended in patients over 12 and under 18 years of age.

CONTRAINDICATIONS

- Patients who are hypersensitive to the active substance (codeine) or other opioid analgesics or any other ingredient in the formulation. For a complete listing, see the **DOSAGE FORMS, COMPOSITION AND PACKAGING** section of the Product Monograph.
- In patients with known or suspected mechanical gastrointestinal obstruction (e.g., bowel obstruction, strictures) or any diseases/conditions that affect bowel transit (e.g., ileus of any type).
- Patients with suspected surgical abdomen (e.g., acute appendicitis or pancreatitis).
- Patients with intermittent or short duration pain that can be managed with other pain medications.
- Patients with acute or mild pain that can be managed with immediate release pain medications.
- Patients with acute or severe bronchial asthma, chronic obstructive airway, and status asthmaticus.
- Patients with acute respiratory depression, elevated carbon dioxide levels in the blood, and cor pulmonale.
- Patients with acute alcoholism, delirium tremens, and convulsive disorders.
- Patients with severe CNS depression, increased cerebrospinal or intracranial pressure, and head injury.
- CYP2D6 ultra-rapid metabolizers who convert codeine into its active metabolite more rapidly and completely than other people (see **WARNINGS AND PRECAUTIONS, Risk of Death in Ultra-Rapid Metabolizers of Codeine; SYMPTOMS AND TREATMENT of OVERDOSAGE, Codeine**)
- Patients taking monoamine oxidase (MAO) inhibitors (or within 14 days of such therapy).
- Women who are breast-feeding, pregnant, or during labour and delivery (see **Serious Warnings and Precautions and Warning and Precautions**).
- Pediatric patients (<18 years of age) who have undergone tonsillectomy and/or adenoidectomy for obstructive sleep apnoea syndrome.

WARNINGS AND PRECAUTIONS

SERIOUS WARNINGS AND PRECAUTIONS

Limitations of Use

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the risks of overdose and death with controlled-release opioid formulations, Codeine Contin[®] (codeine controlled release tablets) should only be used in patients for whom alternative treatment options (e.g., non-opioid analgesics) are

ineffective, not tolerated, or would be otherwise inadequate to provide appropriate management of pain (see DOSAGE AND ADMINISTRATION).

Addiction, Abuse, and Misuse

Codeine Contin poses risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Each patient's risk should be assessed prior to prescribing Codeine Contin, and all patients should be monitored regularly for the development of these behaviours or conditions (see WARNINGS AND PRECAUTIONS). Codeine Contin should be stored securely to avoid theft or misuse.

Life-threatening Respiratory Depression: OVERDOSE

Serious, life-threatening, or fatal respiratory depression may occur with use of Codeine Contin. Infants exposed in-utero or through breast milk are at risk of life-threatening respiratory depression upon delivery or when nursed. Patients should be monitored for respiratory depression, especially during initiation of Codeine Contin or following a dose increase.

Codeine Contin must be swallowed whole; cutting, breaking, crushing, chewing, or dissolving Codeine Contin can lead to dangerous adverse events including death (see WARNINGS AND PRECAUTIONS). Further, instruct patients of the hazards related to taking opioids including fatal overdose.

Accidental Exposure

Accidental ingestion of even one dose of Codeine Contin, especially by children, can result in a fatal overdose of codeine (see DOSAGE AND ADMINISTRATION, Disposal, for instructions on proper disposal).

Neonatal Opioid Withdrawal Syndrome

Prolonged maternal use of Codeine Contin during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening (see WARNINGS AND PRECAUTIONS).

Interaction with Alcohol

The co-ingestion of alcohol with Codeine Contin should be avoided as it may result in dangerous additive effects, causing serious injury or death (see WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS).

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death (see WARNINGS AND PRECAUTIONS, Neurologic and DRUG INTERACTIONS).

- Reserve concomitant prescribing of Codeine Contin and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
- Limit dosages and durations to the minimum required.

- **Follow patients for signs and symptoms of respiratory depression and sedation.**

General

Codeine Contin must be swallowed whole, and should not be chewed, dissolved or crushed. Taking broken, chewed, dissolved or crushed tablets could lead to the rapid release and absorption of a potentially fatal dose of codeine. All strengths may be halved, except 50 mg. The half tablets must also be swallowed intact.

Patients should be instructed not to give Codeine Contin to anyone other than the patient for whom it was prescribed, as such, inappropriate use may have severe medical consequences, including death. Codeine Contin should be stored securely to avoid theft or misuse.

Codeine Contin should only be prescribed by healthcare professionals who are knowledgeable in the continuous administration of potent opioids, in the management of patients receiving potent opioids for the treatment of pain, and in the detection and management of respiratory depression, including the use of opioid antagonists.

Patients should be cautioned not to consume alcohol while taking **Codeine Contin**, as it may increase the chance of experiencing dangerous side effects, including death.

Hyperalgesia that will not respond to a further dose increase of codeine may occur in particular in high doses. A codeine dose reduction or change in opioid may be required.

Patients should be counselled to discontinue codeine products and to seek urgent medical help at the earliest sign of codeine toxicity including symptoms such as confusion, shallow breathing, or extreme sleepiness which may be life threatening.

Abuse and Misuse

Like all opioids, **Codeine Contin** is a potential drug of abuse and misuse, which can lead to overdose and death. Therefore, **Codeine Contin** should be prescribed and handled with caution.

Patients should be assessed for their clinical risks for opioid abuse or addiction prior to being prescribed opioids. All patients receiving opioids should be routinely monitored for signs of misuse and abuse.

Opioids, such as **Codeine Contin**, should be used with particular care in patients with a history of alcohol and illicit/prescription drug abuse. However, concerns about abuse, addiction, and diversion should not prevent the proper management of pain.

Codeine Contin tablets are intended for oral use only. The tablets should be swallowed whole, and not chewed or crushed. With parenteral abuse, the tablet excipients can be expected to result in local tissue necrosis, infection, pulmonary granulomas, and increased risk of endocarditis and

valvular heart injury, which may also be fatal. Abuse of oral dosage forms can be expected to result in serious adverse events, including death.

Carcinogenesis and Mutagenesis

See **TOXICOLOGY** section.

Cardiovascular

Codeine administration may result in severe hypotension in patients whose ability to maintain adequate blood pressure is compromised by reduced blood volume, or concurrent administration of such drugs as phenothiazines and other tranquilizers, sedative/hypnotics, tricyclic antidepressants or general anesthetics. These patients should be monitored for signs of hypotension after initiating or titrating the dose of **Codeine Contin**.

The use of **Codeine Contin** in patients with circulatory shock should be avoided as it may cause vasodilation that can further reduce cardiac output and blood pressure.

Dependence/Tolerance

As with other opioids, tolerance and physical dependence may develop upon repeated administration of **Codeine Contin** and there is potential for development of psychological dependence. **Codeine Contin** should therefore be prescribed and handled with the degree of caution appropriate to the use of a drug with abuse potential.

Physical dependence and tolerance reflect the neuroadaptation of the opioid receptors to chronic exposure to an opioid, and are separate and distinct from abuse and addiction. Tolerance, as well as physical dependence, may develop upon repeated administration of opioids, and are not by themselves evidence of an addictive disorder or abuse.

Patients on prolonged therapy should be tapered gradually from the drug if it is no longer required for pain control. Withdrawal symptoms may occur following abrupt discontinuation of therapy or upon administration of an opioid antagonist. Some of the symptoms that may be associated with abrupt withdrawal of an opioid analgesic include body aches, diarrhea, gooseflesh, loss of appetite, nausea, nervousness or restlessness, anxiety, runny nose, sneezing, tremors or shivering, stomach cramps, tachycardia, trouble with sleeping, unusual increase in sweating, palpitations, unexplained fever, weakness and yawning (see **ADVERSE REACTIONS, DOSAGE AND ADMINISTRATION, Adjustment or Reduction of Dosage**).

Use in Drug and Alcohol Addiction

Codeine Contin is an opioid with no approved use in the management of addictive disorders. Its proper usage in individuals with drug or alcohol dependence, either active or in remission is for the management of pain requiring opioid analgesia.

Patients with a history of addiction to drugs or alcohol may be at higher risk of becoming addicted to **Codeine Contin** unless used under extreme caution and awareness.

Metabolism

Risk of Death in Ultra-Rapid Metabolizers of Codeine: Some individuals, may be ultra-rapid metabolizers due to a specific CYP2D6*2x2 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labelled dosage regimens, individuals who are ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. (See also **Labour, Delivery and Nursing Women in Special Populations**).

The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and inform their patients about these risks and the signs of morphine overdose (see **DOSAGE AND ADMINISTRATION, Dosing Considerations**).

Endocrine

Adrenal Insufficiency: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.

Gastrointestinal Effects

Codeine and other morphine-like opioids have been shown to decrease bowel motility. Codeine may obscure the diagnosis or clinical course of patients with acute abdominal conditions (see **CONTRAINDICATIONS** and **ADVERSE REACTIONS, Nausea and Vomiting and Constipation**).

Neonatal Opioid Withdrawal Syndrome (NOWS)

Prolonged maternal use of opioid during pregnancy can result in withdrawal signs in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening.

Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn.

Use of **Codeine Contin** is contraindicated in pregnant women (see **CONTRAINDICATIONS**).

Neurologic

Interactions with CNS Depressants (including benzodiazepines and alcohol): Codeine should be used with caution and in reduced dosage during concomitant administration of other opioid analgesics, general anesthetics, phenothiazines and other tranquilizers, sedative-hypnotics, tricyclic antidepressants, antipsychotics, antihistamines, benzodiazepines, centrally-active antiemetics and other CNS depressants. Respiratory depression, hypotension and profound sedation, coma or death may result.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics (see **DRUG INTERACTIONS**). If the decision is made to prescribe a benzodiazepine or other CNS depressant concomitantly with an opioid analgesic, prescribe the lowest effective dosages and minimum durations of concomitant use. In patients already receiving an opioid analgesic, prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking a benzodiazepine or other CNS depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response. Follow patients closely for signs and symptoms of respiratory depression and sedation.

Advise both patients and caregivers about the risks of respiratory depression and sedation when **Codeine Contin** is used with benzodiazepines or other CNS depressants (including alcohol and illicit drugs). Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined. Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs (see **DRUG INTERACTIONS**).

Codeine Contin should not be consumed with alcohol as it may increase the chance of experiencing dangerous side effects, including death (see **CONTRAINDICATIONS** with **ADVERSE REACTIONS**, **Sedation**, and **DRUG INTERACTIONS**).

Severe pain antagonizes the subjective and respiratory depressant actions of opioid analgesics. Should pain suddenly subside, these effects may rapidly manifest.

Use in Patients with Convulsive or Seizure Disorders: The codeine in **Codeine Contin** may aggravate convulsions in patients with convulsive disorders, and may induce or aggravate seizures in some clinical settings. Therefore, **Codeine Contin** should not be used in these patients (see **CONTRAINDICATIONS**).

Serotonin Syndrome: **Codeine Contin** could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs (e.g. anti-depressants, migraine medications). Treatment with the serotonergic drug should be discontinued if such events (characterized by clusters of symptoms such as hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes including confusion, irritability, extreme agitation progressing to delirium and coma) occur and supportive symptomatic treatment should be initiated. **Codeine Contin** should not be used in combination with MAO inhibitors or serotonin-precursors (such as L-tryptophan, oxitriptan) and should be used with caution in combination with other serotonergic drugs (triptans, certain tricyclic antidepressants, lithium, tramadol, St. John's Wort) due to the risk of serotonergic syndrome (see **DRUG INTERACTIONS**).

Head Injury: The respiratory depressant effects of codeine and the capacity to elevate cerebrospinal fluid pressure, may be greatly increased in the presence of an already elevated intracranial pressure produced by trauma. Also, codeine may produce confusion, miosis, vomiting and other side effects which obscure the clinical course of patients with head injury. In such patients, codeine must be used with extreme caution and only if it is judged essential (see **CONTRAINDICATIONS**).

Peri-Operative Considerations

Codeine Contin is not indicated for pre-emptive analgesia (administration preoperatively for the management of post-operative pain).

In the case of planned chordotomy or other pain-relieving operations, patients should not be treated with **Codeine Contin** for at least 24 hours before the operation and it should not be used in the immediate post-operative period.

Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. Thereafter, if **Codeine Contin** is to be continued after the patient recovers from the post-operative period a new dosage should be administered in accordance with the changed need for pain relief. The risk of withdrawal in opioid-tolerant patients should be addressed as clinically indicated.

The administration of analgesics in the peri-operative period should be managed by healthcare providers with adequate training and experience (e.g., by an anesthesiologist).

Codeine and other morphine-like opioids have been shown to decrease bowel motility. Ileus is a common post-operative complication, especially after intra-abdominal surgery with opioid analgesia. Caution should be taken to monitor for decreased bowel motility in post-operative patients receiving opioids. Standard supportive therapy should be implemented.

Codeine Contin should not be used in the early post-operative period (12 to 24 hours post-surgery) unless the patient is ambulatory and gastrointestinal function is normal.

Psychomotor Impairment

Codeine Contin may impair the mental and/or physical abilities needed for certain potentially hazardous activities such as driving a car or operating machinery. Patients should be cautioned accordingly. Patients should also be cautioned about the combined effects of codeine with other CNS depressants, including other opioids, phenothiazine, sedative/hypnotics and alcohol.

Respiratory

Respiratory Depression: Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression from opioid use, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status. Codeine should be used with extreme caution in patients with substantially decreased respiratory reserve, pre-existing respiratory depression, hypoxia or hypercapnia (see **CONTRAINDICATIONS**).

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of **Codeine Contin**, the risk is greatest during the initiation of therapy or following a dose increase. Patients should be closely monitored for respiratory depression when initiating therapy with **Codeine Contin** and following dose increases.

Life-threatening respiratory depression is more likely to occur in the elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients.

To reduce the risk of respiratory depression, proper dosing and titration of **Codeine Contin** are essential. Overestimating the **Codeine Contin** dose when converting patients from another opioid product can result in a fatal overdose with the first dose. In these patients, the use of non-opioid analgesics should be considered, if feasible (see **WARNINGS AND PRECAUTIONS, Special Populations, Special Risk Groups, and DOSAGE AND ADMINISTRATION**).

Respiratory depression and death have occurred in children who received codeine in the postoperative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). Children with obstructive sleep apnea who are

treated with codeine for post-tonsillectomy and/or adenoidectomy pain may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine. Codeine-containing products are contraindicated for post-operative pain management in all pediatric patients undergoing tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome (see **CONTRAINDICATIONS**).

Use in Patients with Chronic Pulmonary Disease: Monitor patients with significant chronic obstructive pulmonary disease or cor pulmonale, and patients having a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression for respiratory depression, particularly when initiating therapy and titrating with **Codeine Contin**, as in these patients, even usual therapeutic doses of **Codeine Contin** may decrease respiratory drive to the point of apnea. In these patients, use of alternative non-opioid analgesics should be considered, if possible. The use of **Codeine Contin** is contraindicated in Patients with acute or severe bronchial asthma, chronic obstructive airway, or status asthmaticus (see **CONTRAINDICATIONS**).

Patient Counselling Information

A patient information sheet should be provided when **Codeine Contin** tablets are dispensed to the patient.

Patients receiving **Codeine Contin** should be given the following instructions by the physician:

1. Patients should be informed that accidental ingestion or use by individuals (including children) other than the patient for whom it was originally prescribed, may lead to severe, even fatal, consequences.
2. Patients should be advised that **Codeine Contin** contains codeine, an opioid pain medicine.
3. Patients should be advised that **Codeine Contin** should only be taken as directed. The dose of **Codeine Contin** should not be adjusted without consulting with a physician. If pain occurs between doses, do not take an extra dose of **Codeine Contin** as this could be dangerous.
4. **Codeine Contin** must be swallowed whole (not broken, chewed, dissolved or crushed) due to the risk of fatal codeine overdose. For three of the four dose strengths (100 mg, 150 mg, and 200 mg), the tablet is scored and may be broken in half.
5. Patients should be advised to report episodes of pain and adverse experiences occurring during therapy. Individualization of dosage is essential to make optimal use of this medication.
6. Patients should not combine **Codeine Contin** with alcohol or other central nervous system depressants (sleep aids, tranquilizers) because dangerous additive effects may occur resulting in serious injury or death.

7. Patients should be advised to consult their physician or pharmacist if other medications are being used or will be used with **Codeine Contin**.
8. Patients should be advised that if they have been receiving treatment with **Codeine Contin** and cessation of therapy is indicated, it may be appropriate to taper the **Codeine Contin** dose, rather than abruptly discontinue it, due to the risk of precipitating withdrawal symptoms.
9. Patients should be advised of the most common adverse reactions that may occur while taking **Codeine Contin**: constipation, dizziness, light-headedness, nausea, sedation, sweating and vomiting.
10. Patients should be advised that **Codeine Contin** may cause drowsiness, dizziness, or light-headedness and may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating machinery). Patients started on **Codeine Contin** or patients whose dose has been adjusted should be advised not to drive a car or operate machinery unless they are tolerant to the effects of **Codeine Contin**.
11. Patients should be advised that **Codeine Contin** is a potential drug of abuse. They should protect it from theft or misuse.
12. Patients should be advised that **Codeine Contin** should never be given to anyone other than the individual for whom it was prescribed.
13. Patients should be advised that the maximum daily dose of **Codeine Contin** is 300 mg every 12 hours, and only for individuals tolerant to the effect of equivalent doses of opioids.
14. Women of childbearing potential who become or are planning to become pregnant should be advised to consult a physician prior to initiating or continuing therapy with **Codeine Contin**. Women who are breast-feeding or pregnant should not use **Codeine Contin**.

Sexual Function / Reproduction

Long-term use of opioids may be associated with decreased sex hormone levels and symptoms such as low libido, erectile dysfunction, or infertility (see **ADVERSE REACTIONS, Post-Marketing Experience**)

Special Populations

Special Risk Groups: Codeine should be administered with caution to patients with a history of alcohol and drug abuse and in a reduced dosage to debilitated patients, and in patients with severely impaired pulmonary function, Addison's disease, hypothyroidism, myxedema, toxic psychosis, prostatic hypertrophy or urethral stricture.

Pregnant Women: **Codeine Contin** is contraindicated in patients who are pregnant. Studies in humans have not been conducted. **Codeine Contin** crosses the placental barrier and should not

be administered to pregnant women unless in the judgement of the physician, potential benefits outweigh the risks.

Prolonged maternal use of opioids during pregnancy can result in withdrawal signs in the neonate. Neonatal Opioid Withdrawal Syndrome (NOWS), unlike opioid withdrawal syndrome in adults, may be life-threatening (see **WARNINGS AND PRECAUTIONS, Neonatal Opioid Withdrawal Syndrome (NOWS), ADVERSE REACTIONS**).

Pregnant women using opioids should not discontinue their medication abruptly as this can cause pregnancy complication such as miscarriage or still-birth. Tapering should be slow and under medical supervision to avoid serious adverse events to the fetus.

Labour, Delivery and Nursing Women: Since opioids can cross the placental barrier and also excreted in breast milk. **Codeine Contin** is contraindicated during labour, delivery, pregnancy and in nursing mothers. Life-threatening respiratory depression may occur in the infant if opioids are administered to the mother. Naloxone, a drug that counters the effects of opioids should be readily available if **Codeine Contin** is used in this population.

Nursing Women: **Codeine Contin** is contraindicated in women who are breast-feeding (see **CONTRAINDICATIONS**). Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. **However, some women are ultra-rapid metabolizers of codeine (see WARNINGS AND PRECAUTIONS, Metabolism, Risk of Death in Ultra-Rapid Metabolizers of Codeine). These women achieve higher-than-expected serum levels of codeine's active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breast-fed infants. Mothers using codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breast-feeding, breathing difficulties, and decreased tone, in their baby. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death in nursing infants.**

Since there is a risk of infant exposure to codeine and morphine through breast milk, **Codeine Contin** is contraindicated in breast-feeding. Prescribers should closely monitor mother-infant pairs and notify treating paediatricians about any use of codeine during breast-feeding.

Pediatrics (< 18 years of age): Some children may be ultra-rapid metabolizers of codeine (see **WARNINGS AND PRECAUTIONS, Metabolism, Risk of Death in Ultra-Rapid Metabolizers of Codeine**). Regardless of clinical setting, codeine (including Codeine Contin) should not be used in children below the age of 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine. Codeine Contin has not been studied in the pediatric population, therefore the use of Codeine Contin is not recommended in patients over 12 and under 18 years of age.

Geriatrics (> 65 years of age): In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, and titrated slowly reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see **DOSAGE AND ADMINISTRATION**).

“In Vitro” Dissolution Studies of Interaction with Alcohol

Increasing concentrations of alcohol in the dissolution medium resulted in a slight decrease in the rate of release of codeine from **Codeine Contin** tablets.

Patients with Hepatic Impairment: No formal studies have been conducted in patients with hepatic impairment so the pharmacokinetics of codeine in this patient population are unknown. Start these patients cautiously with lower doses of **Codeine Contin** or with longer dosing intervals and titrate slowly while carefully monitoring for side effects. Dosage reduction is recommended in severe hepatic impairment due to the risk of toxicity.

Patients with Renal Impairment: Dosage reduction is recommended in severe renal impairment due to the risk of toxicity (see **ACTION AND CLINICAL PHARMACOLOGY Special Populations and Conditions, Renal Impairment**).

Codeine pharmacokinetics may be altered in patients with renal failure. Clearance may be decreased and the metabolites may accumulate to much higher plasma levels in patients with renal failure as compared to patients with normal renal function. Start these patients cautiously with lower doses of **Codeine Contin** or with longer dosing intervals and titrate slowly while carefully monitoring for side effects.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

Adverse effects of **Codeine Contin**[®] (codeine controlled release tablets) are similar to those of other opioid analgesics and represent an extension of pharmacological effects of the drug class. The major hazards of opioids include respiratory and central nervous system depression and to a lesser degree, circulatory depression, respiratory arrest, shock and cardiac arrest.

The most frequently observed adverse effects are constipation, dizziness, light-headedness, nausea, sedation, sweating and vomiting.

Sedation: Sedation is a common side effect of opioid analgesics, especially in opioid naïve individuals. Sedation may also occur partly because patients often recuperate from prolonged fatigue after the relief of persistent pain. Most patients develop tolerance to the sedative effects of opioids within three to five days and, if the sedation is not severe, will not require any treatment except reassurance. If excessive sedation persists beyond a few days, the dose of the opioid should be reduced and alternate causes investigated. Some of these are: concurrent CNS depressant medication, hepatic or renal dysfunction, brain metastases, hypercalcemia and respiratory failure. If it is necessary to reduce the dose, it can be carefully increased again after three or four days if it is obvious that the pain is not being well controlled. Dizziness and unsteadiness may be caused by postural hypotension, particularly in elderly or debilitated

patients, and may be alleviated if the patient lies down.

Nausea and Vomiting: Nausea is a common side effect on initiation of therapy with opioid analgesics and is thought to occur by activation of the chemoreceptor trigger zone, stimulation of the vestibular apparatus and through delayed gastric emptying. The prevalence of nausea declines following continued treatment with opioid analgesics. When instituting therapy with an opioid for chronic pain, the routine prescription of an antiemetic should be considered. In the cancer patient, investigation of nausea should include such causes as constipation, bowel obstruction, uremia, hypercalcemia, hepatomegaly, tumor invasion of celiac plexus and concurrent use of drugs with emetogenic properties. Persistent nausea which does not respond to dosage reduction may be caused by opioid-induced gastric stasis and may be accompanied by other symptoms including anorexia, early satiety, vomiting and abdominal fullness. These symptoms respond to chronic treatment with gastrointestinal prokinetic agents.

Constipation: Practically all patients become constipated while taking opioids on a chronic basis. In some patients, particularly the elderly or bedridden, fecal impaction may result. It is essential to caution the patients in this regard and to institute an appropriate regimen of bowel management at the start of prolonged opioid therapy. Stimulant laxatives, stool softeners and other appropriate measures should be used as required. As fecal impaction may present as overflow diarrhea, the presence of constipation should be excluded in patients on opioid therapy prior to initiating treatment for diarrhea.

The following adverse effects occur less frequently with **Codeine Contin** and opioid analgesics, whether related or not to codeine controlled release tablets.

Less Frequently Observed with Opioid Analgesics:

- Dermatologic:** diaphoresis, other skin rashes, pruritus and urticaria
- Cardiovascular:** bradycardia, chills, faintness, flushing of the face, hypertension, hypotension, palpitation, syncope and tachycardia
- Gastrointestinal** anorexia, biliary tract spasm, cramps, diarrhea, dry mouth and taste alterations
- General and CNS:** agitation, alterations of mood (nervousness, apprehension, depression, floating feelings, dreams), blurred vision, diplopia and miosis, dysphoria, euphoria, headache, insomnia, increased intracranial pressure, muscle rigidity, muscle tremor, nystagmus, paresthesia, transient hallucinations and disorientation, tremors, uncoordinated muscle movements, visual disturbances and weakness
- Genitourinary:** antidiuretic effects, urinary retention or hesitancy
- Respiratory:** bronchospasm and laryngospasm

Post-Marketing Experience

Androgen deficiency: Chronic use of opioids may influence the hypothalamic-pituitary-gonadal

axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date. Patients presenting with symptoms of androgen deficiency should undergo laboratory evaluation.

DRUG INTERACTIONS

Overview

Interactions with Central nervous System (CNS) Depressants (including benzodiazepines and alcohol):

Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants (e.g. other opioids, sedatives/hypnotics, antidepressants, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, phenothiazines, neuroleptics, antihistamines, antiemetics, and alcohol) and beta-blockers, increases the risk of respiratory depression, profound sedation, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation (see **WARNINGS AND PRECAUTIONS, Neurologic, Interactions with CNS Depressants (including benzodiazepines and alcohol) and Psychomotor Impairment**).

Codeine Contin[®] (codeine controlled release tablets) should not be consumed with alcohol as it may increase the chance of experiencing dangerous side effects.

Drug-Drug Interactions

Drugs Metabolized by Cytochrome P450 Isozymes: Codeine is converted to morphine by the hepatic cytochrome CYP2D6, hence its safety and efficacy is controlled by this polymorphism, and has a high degree of variability in humans. Given the higher potency of morphine relative to codeine, CYP2D6 activity levels have been associated with outcomes from codeine administration that range from an absence of effect to responses with the potential of serious medical consequences.

Inhibitors of CYP2D6: About 5-10 percent of Caucasians and 1 percent of Asians exhibit the poor metabolizer phenotype. However, a range of CYP2D6 activity levels, including very efficient metabolizers of codeine, have been documented (see **WARNINGS AND PRECAUTIONS, Metabolism, Risk of Death in Ultra-Rapid Metabolizers of Codeine**).

Administration with Mixed Activity Agonist/Antagonist Opioids: Mixed agonist/antagonist opioid analgesics (i.e., pentazocine, nalbuphine, butorphanol, and buprenorphine) should be administered with caution to a patient who has received or is receiving a course of therapy with a pure opioid agonist analgesic such as codeine. In this situation, mixed agonist/antagonist analgesics may reduce the analgesic effect of codeine and/or may precipitate withdrawal symptoms in these patients.

MAO Inhibitors: MAO Inhibitors intensify the effects of opioid drugs which can cause anxiety, confusion and decreased respiration. **Codeine Contin** is contraindicated in patients receiving MAO Inhibitors or who have taken them within the previous 14 days (see **CONTRAINDICATIONS**).

Serotonergic Agents: Coadministration of codeine controlled release tablets with a serotonergic agent, such as a Selective Serotonin Re-uptake Inhibitor or a Serotonin Norepinephrine Re-uptake Inhibitor, may increase the risk of serotonin syndrome, a potentially life-threatening condition (see **WARNINGS AND PRECAUTIONS, Neurologic**).

Warfarin and Other Coumarin Anticoagulants: Codeine may increase the anticoagulant activity of coumarin and other anticoagulants.

Drug-Food Interactions

In the presence of food, the extent of absorption of **Codeine Contin** is not significantly increased but peak concentrations are somewhat delayed, occurring at 3.9 - 4.5 hours post-dose.

Drug-Herb Interactions

Interactions with herbal products have not been established.

Drug-Laboratory Interactions

Interactions with laboratory tests have not been established.

Drug-Lifestyle Interactions

The concomitant use of alcohol should be avoided (see **WARNINGS AND PRECAUTIONS, General**).

DOSAGE AND ADMINISTRATION

All doses of opioids carry an inherent risk of fatal or non-fatal adverse events. This risk is increased with higher doses. For the management of chronic non-cancer, non-palliative pain, it is recommended that 600 mg (90 morphine milligram equivalent) daily of Codeine Contin[®] (codeine controlled release tablets) not be exceeded. Each patient should be assessed for their risk prior to prescribing Codeine Contin, as the likelihood of experiencing serious adverse events can depend upon the type of opioid, duration of treatment, level of pain as well as the patient's own level of tolerance. In addition, the level of pain should be assessed routinely to confirm the most appropriate dose and the need for

further use of Codeine Contin (see **DOSAGE AND ADMINISTRATION - Adjustment or Reduction of Dosage**).

Codeine Contin should only be used in patients for whom alternative treatment options are ineffective or not tolerated (e.g., non-opioid analgesics).

Codeine Contin must be swallowed whole and should not be chewed, dissolved or crushed. Taking broken, chewed, dissolved or crushed tablets could lead to rapid release and absorption of a potentially fatal dose of codeine (see **WARNINGS AND PRECAUTIONS**). All strengths may be halved, except 50 mg. The half tablets must also be swallowed intact.

Children under 12: Regardless of clinical setting, codeine (including Codeine Contin) should not be used in children below the age of 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine (see **INDICATIONS**).

Dosing Considerations

Codeine Contin (codeine controlled release tablets) should be used with caution within 12 hours pre-operatively but should not be used in the early post-operative period (12 to 24 hours post-surgery) unless the patient is ambulatory and gastrointestinal function is normal (see **WARNINGS AND PRECAUTIONS, Peri-operative Considerations**).

Codeine Contin is not indicated for rectal administration.

Codeine Contin should not be used in individuals less than 18 years old.

Codeine Contin may be taken with or without food with a glass of water.

Recommended Dose and Dosage Adjustment

Adults: Individual dosing requirements vary considerably based on each patient's age, weight, severity and cause of pain, and medical and analgesic history.

Doses of Codeine Contin are expressed as codeine base. Codeine phosphate formulations contain approximately 75% codeine base. Patients currently receiving oral immediate release formulations of plain codeine phosphate may be transferred to Codeine Contin at an approximately 25% lower total daily codeine dosage, equally divided into two 12 hourly Codeine Contin doses.

Patients Not Receiving Opioids at the Time of Initiation of Codeine Treatment: Patients with pain who are not currently receiving other opioid analgesics, or who are receiving fewer than four tablets per day of a codeine combination preparation, should be initiated at a dose of Codeine Contin 50 mg every 12 hours and the dose titrated as needed.

Patients Currently Receiving Opioids: For patients who are currently receiving analgesic combinations of codeine phosphate and acetaminophen or acetylsalicylic acid (ASA.), Table 1 provides a guide to the recommended initial and maintenance doses of Codeine Contin.

Table 1: Conversion from Acetaminophen (or ASA) plus Codeine Phosphate Combinations

Number of 30 mg Codeine Combination Tablets per Day	Initial Dose of Codeine Contin	Maintenance Dose of Codeine Contin
4 – 6	50 mg q12h	100 mg q12h
7 – 9	100 mg q12h	150 mg q12h
10 – 12	150 mg q12h	200 mg q12h
>12	200 mg q12h	as needed (maximum 300 mg q12h)

For patients who are receiving an alternate opioid, the "oral codeine phosphate equivalent" of the analgesic presently being used should be determined. Having determined the total daily dosage of the present analgesic, Table 2 can be used to calculate the approximate daily oral codeine phosphate dosage that should provide equivalent analgesia. An approximately 25% lower dose of **Codeine Contin** should then be prescribed, to account for the change from codeine phosphate to codeine base. This dose should be equally divided into two 12 hourly doses. Further dose reductions should also be considered due to incomplete cross-tolerance between opioids.

Opioid Rotation: Conversion ratios for opioids are subject to variations in kinetics governed by genetics and other factors. When switching from one opioid to another, consider **reducing the calculated dose by 25-50%** to minimize the risk of overdose. Subsequently, up-titrate the dose, as required, to reach the appropriate maintenance dose.

Table 2: Opioid Conversion Table^a

Opioids	To convert to oral morphine equivalent	To convert from oral morphine multiply by	Daily 90 mg MED^b
Morphine	1	1	90 mg
Codeine	0.15	6.67	600 mg
Hydromorphone	5	0.2	18 mg
Oxycodone	1.5	0.667	60 mg
Tapentadol	0.3-0.4	2.5-3.33	300 mg
Tramadol	0.1-0.2	6	***
Methadone	Morphine dose equivalence is not reliably established		

*** The maximum recommended daily dose of tramadol is 300 mg – 400 mg depending on the formulation.

a. Adapted from the 2017 Canadian guideline for opioids for chronic non-cancer pain. McMaster University; 2017

b. MED. Morphine Equivalent Dose

Patients with Hepatic Impairment: Start these patients cautiously with lower doses of **Codeine Contin** or with longer dosing intervals and titrate slowly while carefully monitoring for side effects. Dosage reduction is recommended in severe hepatic impairment due to the risk of toxicity (see **ACTION AND CLINICAL PHARMACOLOGY Special Populations and Conditions, Hepatic Impairment**).

Patients with Renal Impairment: Dosage reduction is recommended in severe renal impairment due to the risk of toxicity (see **ACTION AND CLINICAL PHARMACOLOGY Special Populations and Conditions, Renal Impairment**).

Clearance may be decreased and the metabolites may accumulate to much higher plasma levels in patients with renal failure as compared to patients with normal renal function. Start these patients cautiously with lower doses of **Codeine Contin** or with longer dosing intervals and titrate slowly while carefully monitoring for side effects.

Geriatrics: Respiratory depression has occurred in the elderly following administration of large initial doses of opioids to patients who were not opioid-tolerant or when opioids were co-administered with other agents that can depress respiration. **Codeine Contin** should be initiated at a low dose and slowly titrated to effect (see **WARNINGS AND PRECAUTIONS** and **ACTION AND CLINICAL PHARMACOLOGY**).

Use with Non-Opioid Medications: If a non-opioid analgesic is being provided, it may be continued. If the non-opioid is discontinued, consideration should be given to increasing the opioid dose to compensate for the non-opioid analgesic. **Codeine Contin** can be safely used concomitantly with usual doses of other non-opioid analgesics.

Dose Titration: Dose titration is the key to success with opioid analgesic therapy. **Proper optimization of doses scaled to the relief of the patient's pain should aim at regular administration of the lowest dose of controlled release codeine (Codeine Contin) which will achieve the overall treatment goal of satisfactory pain relief with acceptable side effects.**

Dosage adjustments should be based on the patient's clinical response. In patients receiving **Codeine Contin** chronically, the dose should be titrated at intervals of 48 hours to that which provides satisfactory pain relief without unmanageable side effects. Doses of **Codeine Contin** above 300 mg q12h have not been extensively studied, and above these levels it is preferable that patients be transferred to an opioid such as morphine, which is recommended for severe pain. **Codeine Contin** is designed to allow 12 hourly dosing.

If pain repeatedly occurs at the end of the dosing interval it is generally an indication for a dosage increase rather than more frequent administration of controlled release codeine (Codeine Contin).

Adjustment or Reduction of Dosage: Physical dependence with or without psychological dependence tends to occur with chronic administration of opioids, including **Codeine Contin**. Withdrawal (abstinence) symptoms may occur following abrupt discontinuation of therapy. These symptoms may include body aches, diarrhea, gooseflesh, loss of appetite, nausea, nervousness or restlessness, runny nose, sneezing, tremors or shivering, stomach cramps, tachycardia, trouble with sleeping, unusual increase in sweating, palpitations, unexplained fever, weakness and yawning.

Following successful relief of pain, periodic attempts to reduce the opioid dose should be made. Smaller doses or complete discontinuation may become feasible due to a change in the patient's condition or mental state.

Patients on prolonged therapy should be withdrawn gradually from the drug if it is no longer required for pain control. In patients who are appropriately treated with opioid analgesics and who undergo gradual withdrawal for the drug, these symptoms are usually mild (see **WARNINGS AND PRECAUTIONS**). Tapering should be individualized and carried out under medical supervision.

Patients should be informed that reducing and/or discontinuing opioids decreases their tolerance to these drugs. If treatment needs to be re-initiated, the patient must start at the lowest dose and titrate up to avoid overdose.

Opioid analgesics may only be partially effective in relieving dysesthetic pain, postherpetic neuralgia, stabbing pains, activity-related pain and some forms of headache. That is not to say that patients suffering from some of these forms of chronic pain should not be given an adequate trial of opioid analgesics, but it may be necessary to refer such patients at an early time to other forms of pain therapy.

Management of Patients Requiring Rescue Medication: For patients whose dose has been titrated to the recommended maintenance dose, without attainment of adequate analgesia, the total daily dose may be increased, unless precluded by side effects. If episodes of pain are encountered with appropriate adjustments of the **Codeine Contin** dose, plain acetaminophen may be given (325-650 mg q4-6h p.r.n. to a maximum of 4,000 mg/24 hours). Fentanyl products should not be used as rescue medication in patients taking **Codeine Contin**. If immediate release codeine phosphate preparations or acetaminophen plus codeine phosphate combination analgesics (q4-6h p.r.n.) are used for pain, the doses of codeine phosphate* are 15, 30, 45, 60, 90 mg for patients receiving **Codeine Contin** 100, 200, 300, 400, 600 mg/day, respectively.

(*based on a rescue medication dose of codeine base which should not exceed $\frac{1}{8}$ of the daily dose of **Codeine Contin**.)

Missed Dose

If the patient forgets to take one or more doses, they should take their next dose at the next scheduled time and in the normal amount.

Disposal

Codeine Contin should be kept in a safe place, such as under lock and out of the sight and reach of children before, during and after use. **Codeine Contin** should not be used in front of children, since they may copy these actions.

Codeine Contin should never be disposed of in household trash. Disposal via a pharmacy take back program is recommended. Unused or expired **Codeine Contin** should be properly disposed of as soon as it is no longer needed to prevent accidental exposure to others, including children or pets. **Codeine Contin** should not be shared with others and steps should be taken to protect it from theft or misuse. The patient should speak to their pharmacist about temporary storage options, if required, until the medication can be returned to the pharmacy for safe disposal.

OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Symptoms: Serious overdose with opioids may be characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), dizziness, confusion, extreme somnolence progressing to stupor or coma, miosis, hypotonia, cold and clammy skin, and sometimes bradycardia and hypotension. Severe overdose may result in apnea, circulatory collapse, cardiac arrest and death.

Treatment: Primary attention should be given to the establishment of adequate respiratory exchange through the provision of a patent airway and controlled or assisted ventilation. The opioid antagonist naloxone hydrochloride is a specific antidote against respiratory depression due to overdose or as a result of unusual sensitivity to opioids. An appropriate dose of the antagonist should therefore be administered, preferably by the intravenous route. The usual initial i.v. adult dose of naloxone is 0.4 mg or higher. Concomitant efforts at respiratory resuscitation should be carried out. Since the duration of action of opioids, particularly sustained release formulations, may exceed that of the antagonist, the patient should be under continued surveillance and doses of the antagonist should be repeated as needed to maintain adequate respiration.

An antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular depression. Oxygen, intravenous fluids, vasopressors and other supportive measures should be used as indicated.

In individuals physically dependent on opioids, the administration of the usual dose of opioid antagonist will precipitate an acute withdrawal syndrome. The severity of this syndrome will depend on the degree of physical dependence and the dose of antagonist administered. The use of opioid antagonists in such individuals should be avoided if possible. If an opioid antagonist must be used to treat serious respiratory depression in the physically dependent patient, the

antagonist should be administered with extreme care by using dosage titration, commencing with 10 to 20% of the usual recommended initial dose.

Evacuation of gastric contents may be useful in removing unabsorbed drug, particularly when a sustained release formulation has been taken.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Codeine is an opioid analgesic which exerts an agonist effect at specific, saturable opioid receptors in the CNS and other tissues. In man, codeine produces a variety of effects including analgesia, constipation from decreased gastrointestinal motility, suppression of the cough reflex, respiratory depression from reduced responsiveness of the respiratory center to CO₂, nausea and vomiting via stimulation of the CTZ, changes in mood including euphoria and dysphoria, sedation, mental clouding, miosis and alterations of the endocrine and autonomic nervous systems.

Pharmacodynamics

Cardiovascular System: Codeine may produce release of histamine with or without associated peripheral vasodilation. Manifestations of histamine release and/or peripheral vasodilatation may include pruritus, flushing, red eyes, hyperhidrosis and/or orthostatic hypotension.

Central Nervous System: Codeine produces respiratory depression by direct action on brain stem respiratory centres. The respiratory depression involves both a reduction in the responsiveness of the brain stem centres to increases in CO₂ tension and to electrical stimulation.

Codeine depresses the cough reflex by direct effect on the cough centre in the medulla. Antitussive effects may occur with doses lower than those usually required for analgesia.

Codeine causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked mydriasis rather than miosis may be seen with hypoxia in the setting of codeine overdose.

Endocrine System: Opioids may influence the hypothalamic-pituitary-adrenal or -gonadal axes. Some changes that can be seen include an increase in serum prolactin, and decreases in plasma cortisol and testosterone. Clinical signs and symptoms may be manifest from these hormonal changes.

Gastrointestinal Tract and Other Smooth Muscle: Codeine causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid-induced effects may include a reduction in gastric, biliary and pancreatic secretions, spasm of the sphincter of Oddi, and transient elevations

in serum amylase.

Immune System: In vitro and animal studies indicate that opioids have a variety of effects on immune functions, depending on the context in which they are used. The clinical significance of these findings is unknown.

Pharmacokinetics

Absorption: Codeine is readily absorbed from the gastrointestinal tract and has an oral bioavailability of 53%, relative to the intramuscular route.

Codeine Contin[®] (codeine controlled release tablets) is absorbed to an equivalent extent as immediate-release tablet or liquid formulations of codeine. In single dose studies in fasting, healthy volunteers, the maximum plasma codeine concentration (C_{max}) is approximately 56% of that from immediate-release formulations and is achieved approximately 2.6 times later - at 3.3 hours post-dosing. In steady-state studies in healthy volunteers, both the extent of absorption and maximum plasma codeine concentrations are equivalent to those from immediate-release formulations at the same total daily dose. In the presence of food, the extent of absorption of **Codeine Contin** is not significantly increased but peak concentrations are somewhat delayed, occurring at 3.9 - 4.5 hours post-dose.

Distribution: Codeine is rapidly distributed from blood to body tissues, passes the blood-brain barrier and is found in fetal tissue and breast milk. Codeine is metabolized in the liver to morphine and norcodeine, each representing about 10% of the administered dose of codeine.

Metabolism: Codeine is metabolized in the liver to morphine and norcodeine, each representing about 10% of the administered dose of codeine. Codeine is converted to morphine by the hepatic cytochrome CYP2D6, hence its safety and efficacy is controlled by this polymorphism, and has a high degree of variability in humans. CYP2D6 activity levels have been associated with outcomes from codeine administration that range from an absence of effect to responses with the potential of serious medical consequences (see **DRUG INTERACTIONS, Drug-Drug Interactions**).

Excretion: Urinary excretion products are free and glucuronide-conjugated codeine (about 70%), free and conjugated morphine (about 10%), normorphine (under 4%) and hydrocodone (<1%). The remainder of the dose appears in the feces.

Special Populations and Conditions

Pediatrics: Some children may be ultra-rapid metabolizers of codeine (see **WARNINGS AND PRECAUTIONS, Metabolism, Risk of Death in Ultra-Rapid Metabolizers of Codeine**). Regardless of clinical setting, codeine (including Codeine Contin) should not be used in children below the age of 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine. Codeine Contin has not been studied in the pediatric population, therefore the use of Codeine Contin is not recommended in patients over 12 and under 18 years of age.

Geriatrics: Codeine should be administered with caution, and in reduced dosages, to elderly or debilitated patients. Respiratory depression has occurred in the elderly following administration of large initial doses of opioids to patients who were not opioid-tolerant or when opioids were co-administered with other agents that can depress respiration. **Codeine Contin** should be initiated at a low dose and slowly titrated to effect (see **WARNINGS AND PRECAUTIONS** and **ACTION AND CLINICAL PHARMACOLOGY**).

Hepatic Impairment: As formal studies have not been conducted in patients with hepatic impairment, the pharmacokinetics of codeine in this patient population are unknown. Therefore, these patients should be started cautiously with lower doses of **Codeine Contin** or with longer dosing intervals and titrate slowly while carefully monitoring for side effects. Dosage reduction is recommended in severe hepatic impairment due to the risk of toxicity.

Renal Impairment: Codeine pharmacokinetics may be altered in patients with renal failure. Clearance may be decreased and the metabolites may accumulate to much higher plasma levels in patients with renal failure as compared to patients with normal renal function. Start these patients cautiously with lower doses of **Codeine Contin** or with longer dosing intervals and titrate slowly while carefully monitoring for side effects.

Gender: No data available.

Race: About 5-10 percent of Caucasians and 1 percent of Asians exhibit the poor metabolizer phenotype and do not convert codeine to morphine sufficiently to benefit from the analgesic effect of the drug (see **DRUG INTERACTIONS, Drug-Drug Interactions**). However, some individuals may be ultra-rapid metabolizers of codeine due to a specific CYP2D6 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people leading to higher-than-expected serum morphine levels. The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese, Japanese and Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups (see **WARNINGS AND PRECAUTIONS, Special Populations, Nursing Women**).

Genetic Polymorphism: Some individuals may be ultra-rapid metabolizers of codeine due to a specific CYP2D6 genotype (see **Special Populations and Conditions, Race** above and **WARNINGS AND PRECAUTIONS, Special Populations, Nursing Women**).

STORAGE AND STABILITY

Store at room temperature (15°C - 30°C).

SPECIAL HANDLING INSTRUCTIONS

Not applicable.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Dosage Forms

Codeine Contin[®] (codeine controlled release tablets) is available in 50 mg (blue), 100 mg (yellow), 150 mg (red) and 200 mg (orange) strengths.

The tablets are film-coated with the following appearance:

- 50 mg - Blue, round, film coated tablets with PF imprinted on one side and CC 50 on the other side.
- 100 mg - Yellow, round, scored film coated tablets with PF imprinted on one side and CC 100 on the other side.
- 150 mg - Red, round, scored film coated tablets with PF imprinted on one side and CC 150 on the other side.
- 200 mg - Orange, caplet shaped, scored film coated tablets with PF imprinted on one side and CC 200 on the other side.

Composition

Codeine Contin 50 mg tablets contain 26.5 mg of codeine monohydrate and 31.35 mg of codeine sulfate trihydrate (each equivalent to 25 mg codeine anhydrous).

Codeine Contin 100 mg tablets contain 53 mg of codeine monohydrate and 62.7 mg of codeine sulfate trihydrate (each equivalent to 50 mg codeine anhydrous).

Codeine Contin 150 mg tablets contain 79.5 mg of codeine monohydrate and 94.1 mg of codeine sulfate trihydrate (each equivalent to 75 mg codeine anhydrous).

Codeine Contin 200 mg tablets contain 106 mg of codeine monohydrate and 125.4 mg of codeine sulfate trihydrate (each equivalent to 100 mg codeine anhydrous).

Non-medicinal ingredients (all tablet strengths): hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, polyethylene glycol, stearyl alcohol, talc and titanium dioxide.

In addition, the tablet strengths listed below contain the following dyes:

- 50 mg - FD&C Blue No. 2 Aluminum Lake
- 100 mg - D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake
- 150 mg - FD&C Yellow No. 6 Aluminum Lake, FD&C Red No. 40 Aluminum Lake
- 200 mg - FD&C Yellow No. 6 Aluminum Lake

Packaging

Supplied in opaque, plastic bottles containing 50 or 60 tablets.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION


Drug Substance(s)

Proper Name: Codeine Monohydrate

Chemical Name: 7, 8-Didehydro-4, 5 α -epoxy-3-methoxy-17-methylmorphinan-6 α -ol monohydrate

Molecular Formula and Molecular Mass: C₁₈H₂₁NO₃ • H₂O / 317.38

Structural Formula:



Physicochemical Properties:

Appearance: Colourless or white crystals or white, crystalline powder.

Solubility: Slightly soluble in water, very soluble in chloroform and freely soluble in ether.


Melting Point: 154° - 158°C.

Proper Name: Codeine Sulfate Trihydrate

Chemical Name: 7, 8-Didehydro-4, 5 α -epoxy-3-methoxy-17-methylmorphinan-6 α -ol sulfate trihydrate

Molecular Formula and Molecular Mass: (C₁₈H₂₁NO₃)₂•H₂SO₄•3H₂O / 750.87

Structural Formula:



Physicochemical Properties:

Appearance: White crystals or white, crystalline powder.

Solubility: Slightly soluble in water, freely soluble in water at 80°C, very slightly soluble in alcohol, insoluble in chloroform and in ether.

Melting Point: 278°C (anhydrous)

CLINICAL TRIALS

The analgesic efficacy of **Codeine Contin**[®] (codeine controlled release tablets) has been evaluated in multiple dose studies in patients with cancer pain and chronic non-malignant pain. In a dose-response study in cancer patients, **Codeine Contin** 150 mg every 12 hours provided approximately equivalent analgesia to 600 mg acetaminophen plus 60 mg codeine every 6 hours. In patients with cancer pain and chronic non-malignant pain receiving q4h p.r.n. acetaminophen plus codeine, **Codeine Contin** (100, 150 or 200 mg every 12 hours) produced improved pain control and reduced consumption of supplementary acetaminophen plus codeine. In patients with chronic low back pain, **Codeine Contin** (100 mg every 12 hours), supplemented with p.r.n. plain acetaminophen, produced lower pain scores and less fluctuation in pain throughout the day than p.r.n. acetaminophen plus codeine.

DETAILED PHARMACOLOGY

Pharmacodynamics

Codeine and related opioids produce their major effects on the CNS and bowel by acting as agonists at specific saturable opioid receptors in the CNS and other tissues, particularly at the μ receptors. The mechanism of action of opioids for analgesia is not at peripheral loci but rather at the level of the spinal cord and higher nerve centers where they are thought to alter the transmission of nerve impulses. The antitussive properties of codeine may be exerted not through the μ receptors but other receptors that are not naloxone sensitive.

It has been speculated that the analgesic effectiveness of codeine is mediated partially by morphine, which is a metabolite of codeine. However, recent studies identifying endogenous formation of codeine and binding of codeine and its metabolites to μ receptors are supportive of an analgesic effect of codeine itself.

Orally administered codeine is approximately 60% as potent as intramuscular codeine in terms of total analgesia. The relative potency of codeine phosphate administered intramuscularly is approximately $1/12$ that of intramuscularly administered morphine sulfate and orally, 200 mg of codeine phosphate is equivalent to 20 - 30 mg of morphine sulfate during chronic dosing.

MICROBIOLOGY

Not applicable.

TOXICOLOGY

Animal

The LD50 of oral codeine in mice and rats, as determined by 15 different investigators, was between 237-640 mg/kg. Animal studies with a number of opioids, including codeine, have indicated the possibility of teratogenic effect. No adequate long-term studies have been conducted in animals to determine whether codeine has a potential for carcinogenesis.

Human

Codeine toxicity may result from overdosage but because of great interindividual variation in sensitivity to opioids it is difficult to determine the exact dose of any opioid that is toxic or lethal.

REFERENCES

1. Arkininstall W, Sandler A, Goughnour B, Babul N, Harsanyi Z, Darke AC. Efficacy of controlled release codeine in chronic nonmalignant pain: A randomized, placebo-controlled clinical trial. *Pain* 1995;62:169-78.
2. Band CJ, Band PR, Deschamps M, Besner J-G, Coldman AJ. Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (Codeine Contin) codeine. *J Clin Pharmacol* 1994;34:938-43.
3. Beaver WT, Wallenstein SL, Rogers A, Houde RW. Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone. *J Pharmacol Exp Ther* 1978;207(1):92-100.
4. Chary S, Goughnour BR, Moulin DE, Thorpe WR, Harsanyi Z, Darke AC. The dose-response relationship of controlled-release codeine (Codeine Contin) in chronic cancer pain. *J Pain Symptom Manage* 1994;9:363-71.
5. Chau TT, Carter FE, Harris LS. 3H-Codeine binding in the guinea pig lower brain stem. *Pharmacology* 1982; 25:12-17.
6. Dhaliwal HS, Sloan P, Arkininstall WW, Thirlwell MP, Babul N, Harsanyi Z, et al. Randomized evaluation of controlled-release codeine and placebo in chronic cancer pain. *J Pain Symptom Manage* 1995;10:612-23.
7. Eddy NB, Friebel H, Hahn K, Halbach H. Codeine and its alternates for pain and cough relief. *Bull WHO* 1968;38:673-741.
8. Findlay JWA, Butz RF, Welch RM. Specific radioimmunoassays for codeine and morphine. Metabolism of codeine to morphine in the rat. *Res Commun Chem Pathol Pharmacol* 1977;17(4):595-603.
9. Findlay JWA, Butz RF, Welch RM. Codeine kinetics as determined by radioimmunoassay. *Clin Pharmacol Ther* 1977;22(4):439-46.
10. Findlay JWA, Jones EC, Butz RF, Welch RM. Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. *Clin Pharmacol Ther* 1978;24(1):60-8.
11. Guay DRP, Awni WM, Halstenson CE, Findlay JW, Opsahl JA, Abraham PA, et al. Pharmacokinetics of codeine after single-and multiple-oral-dose administration to normal volunteers. *J Clin Pharmacol* 1987;27:983-7.

12. Hale ME, Speight KL, Harsanyi Z, Iwan T, Slagle S, Lacouture PG, Darke AC. Efficacy of 12 hourly controlled-release codeine compared with as required dosing of acetaminophen plus codeine in patients with chronic low back pain. *Pain Res Manage* 1997; 2:33-8.
13. Hull JH, Findlay JW, Rogers JF, Welch RM, Butz RF, Bustrack JA. An evaluation of the effects of smoking on codeine pharmacokinetics and bioavailability in normal human volunteers. *Drug Intell Clin Pharm* 1982;16:849-50.
14. Jaffe JH, Martin WR. Narcotic analgesics and antagonists. In: Goodman LS, Gilman A, eds. *The pharmacological basis of therapeutics*, 5th ed, New York: Macmillan Press, 1975:245.
15. Kay DC, Gorodetzky CW, Martin WR. Comparative effects of codeine and morphine in man. *J Pharmacol Exp Ther* 1967;156(1):101-6.
16. Portenoy RK. Chronic opioid therapy in non-malignant pain. *J Pain Symptom Manage* 1990;5:S46-S62.
17. Portenoy RK, Foley KM, Inturissi CE. The nature of opioid responsiveness and its implication for neuropathic pain: New hypotheses derived from studies of opioid infusions. *Pain* 1990;43:273-86.
18. Portenoy RK. Cancer Pain: Pathophysiology and syndromes. *Lancet* 1992;339:1026-31.
19. Quiding H, Oikarinen V, Sane J, Sjöblad A-M. Analgesic efficacy after single and repeated doses of codeine and acetaminophen. *J Clin Pharmacol* 1984;24:27-34.
20. Quiding H, Anderson P, Bondesson U, Boréus LO, Hynning P-Å. Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration. *Eur J Clin Pharmacol* 1986;30:673-7.
21. Quiding H, Lundqvist G, Boreus LO, Bondesson U, Ohrvik J. Analgesic effect and plasma concentrations of codeine and morphine after two dose levels of codeine following oral surgery. *Eur J Clin Pharmacol* 1993;44:319-23.
22. Scott JF, ed. *Cancer Pain: A Monograph on the Management of Cancer Pain*: Ministry of Supply and Services Canada. 1984 Cat. No. H42-2/5-1984E.
23. Sunshine A, Laska EM, Olsen NZ. Analgesic effects of oral oxycodone and codeine in the treatment of patients with postoperative, postfracture, or somatic pain. In: Foley KM and Inturissi CE., eds. *Advances in pain research and therapy*. Vol. 8. Raven Press, New York, 1986;225-34.

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PATIENT MEDICATION INFORMATION

^NCodeine Contin[®]

Codeine Controlled Release Tablets

Read this carefully before you start taking **Codeine Contin** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Codeine Contin**.

Serious Warnings and Precautions

- **Even if you take Codeine Contin as prescribed you are at a risk for opioid addiction, abuse and misuse. This can lead to overdose and death. To understand your risk of opioid addiction, abuse, and misuse you should speak to your prescriber (e.g., doctor).**
- **Life-threatening breathing problems while taking Codeine Contin, especially if not taken as directed. Babies are at risk of life-threatening breathing problems if their mothers take opioids while pregnant or nursing.**
- **Never give anyone your Codeine Contin. They could die from taking it. If a person has not been prescribed Codeine Contin, taking even one dose can cause a fatal overdose. This is especially true for children.**
- **If you took Codeine Contin while you were pregnant, whether for short or long periods of time or in small or large doses, your baby can suffer life-threatening withdrawal symptoms after birth. This can occur in the days after birth and for up to 4 weeks after delivery. If your baby has any of the following symptoms:**
 - **has changes in their breathing (such as weak, difficult or fast breathing)**
 - **is unusually difficult to comfort**
 - **has tremors (shakiness)**
 - **has increased stools, sneezing, yawning, vomiting, or fever**

Seek immediate medical help for your baby.

- **Taking Codeine Contin with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.**

What is Codeine Contin used for?

Codeine Contin is a medicine used to manage your pain.

Codeine Contin is NOT used (“as needed”) to treat pain that you only have once in a while.

How does Codeine Contin work?

Codeine Contin contains codeine which is a pain medication belonging to the class of drugs known as opioids which includes fentanyl, hydromorphone, morphine and oxycodone. It relieves pain by acting on specific nerve cells of the spinal cord and brain.

What are the ingredients in Codeine Contin?

Medicinal ingredient: codeine

Non-medicinal ingredients (all tablet strengths): hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, polyethylene glycol, stearyl alcohol, talc and titanium dioxide.

In addition, the tablet strengths listed below contain the following dyes:

50 mg - FD&C Blue No. 2 Aluminum Lake

100 mg - D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake

150 mg - FD&C Yellow No. 6 Aluminum Lake, FD&C Red No. 40 Aluminum Lake

200 mg - FD&C Yellow No. 6 Aluminum Lake

Codeine Contin comes in the following dosage forms:

Codeine Contin Controlled Release Tablets: 50 mg, 100 mg, 150 mg and 200 mg.

Do not use Codeine Contin if:

- your doctor did not prescribe for you
- you are allergic to codeine, other opioids, or any of the other ingredients in **Codeine Contin**
- you have mild or short term pain that can be controlled by the occasional use of pain medications, including those available without a prescription
- you have severe asthma, trouble breathing, or other lung problems
- you have a condition where the small bowel does not work properly (paralytic ileus) or you have severe pain in your abdomen
- you have a head injury
- you are at risk for seizures
- you suffer from alcoholism
- you are going to have, or recently had, a planned surgery

- you are taking or have taken within the past 2 weeks a monoamine oxidase inhibitor (such as phenelzine sulfate, tranylcypromine sulfate, moclobemide or selegiline)
- you had surgery within the last 12-24 hours or are going to have a planned surgery
- you are pregnant or planning to become pregnant, or in labour
- you are breastfeeding. The use of codeine-containing products while breast-feeding may harm your baby. If you breastfeed and take **Codeine Contin** seek immediate medical care for your baby if they are overly drowsy, sedated, have difficulty breast-feeding, have breathing difficulties, and are floppy (have decreased muscle tone). This is very serious for the baby and can lead to death. Tell the baby's doctor that you are breastfeeding and took **Codeine Contin**.
- you are under 12 years of age
- you are under 18 years old and are having (or have recently had) your tonsils or adenoids removed because of frequent interruption of breathing during sleep

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Codeine Contin. Talk about any health conditions or problems you may have, including if you:

- have a history of illicit or prescription drug or alcohol abuse
- have severe kidney, liver, lung disease
- have heart disease
- have low blood pressure
- have past or current depression
- suffer from chronic or severe constipation
- have problems with your thyroid, adrenal or prostate gland
- have, or had in the past hallucinations or other severe mental problems
- suffer from migraines
- are planning to become pregnant

Other warnings you should know about:

Some people metabolize codeine at a much faster rate than the general population, which may lead to accidental overdose, if this should happen to you, seek help immediately (see **Overdose, for symptoms of overdose and what to do if it happens). If you know that you metabolize codeine rapidly, tell your doctor **BEFORE** starting this medication.**

Codeine Contin is not recommended for anyone who has or is at risk for breathing problems such as:

- lung infections, or respiratory conditions
- neuromuscular disorders
- severe heart problems
- recent multiple traumas or extensive surgical procedures

Opioid dependence and addiction: There are important differences between physical dependence and addiction. It is important that you talk to your doctor if you have questions or concerns about abuse, addiction or physical dependence.

Pregnancy, nursing, labour and delivery: Do not use **Codeine Contin** while pregnant, nursing, during labour or delivery. Opioids can be transferred to your baby through breast milk, or while still in the womb. **Codeine Contin** can then cause life-threatening breathing problems in your unborn baby or nursing infant.

Driving and using machines: Before you do tasks which may require special attention, you should wait until you know how you react to **Codeine Contin**. **Codeine Contin** can cause:

- drowsiness
- dizziness or
- light headedness

This can usually occur after you take your first dose and when your dose is increased.

Disorder of the adrenal gland: You may develop a disorder of the adrenal gland called adrenal insufficiency. This means that your adrenal gland is not making enough of certain hormones. You may experience symptoms such as:

- nausea, vomiting
- feeling tired, weak or dizzy
- decreased appetite

You may be more likely to have problems with your adrenal gland if you have been taking opioids for longer than one month. Your doctor may do tests, give you another medication, and slowly take you off **Codeine Contin**.

Serotonin Syndrome: **Codeine Contin** can cause serotonin syndrome, a rare but potentially life-threatening condition. It can cause serious changes in how your brain, muscles and digestive system work. You may develop serotonin syndrome if you take **Codeine Contin** with certain anti-depressants or migraine medications.

Serotonin syndrome symptoms include:

- fever, sweating, shivering, diarrhea, nausea, vomiting;
- muscle shakes, jerks, twitches or stiffness, overactive reflexes, loss of coordination;
- fast heartbeat, changes in blood pressure;
- confusion, agitation, restlessness, hallucinations, mood changes, unconsciousness, and coma.

Sexual Function/Reproduction: Long term use of opioids may lead to a decrease in sex hormone levels. It may also lead to low libido (desire to have sex), erectile dysfunction or being infertile.

Tell your healthcare professional about all the medicines you take, including any drugs,

vitamins, minerals, natural supplements or alternative medicines.

The following may interact with Codeine Contin:

- alcohol. This includes prescription and non-prescription medications that contain alcohol. **Do not** drink alcohol while you are taking **Codeine Contin**. It can lead to
 - drowsiness
 - unusually slow or weak breathing
 - serious side effects or
 - a fatal overdose
- other sedative drugs which may enhance the drowsiness caused by **Codeine Contin**
- other opioid analgesics (for pain)
- general anesthetics (used during surgery)
- drugs used to help you sleep or that help reduce anxiety
- antidepressants (for depression and mood disorders). **Do not** take **Codeine Contin** with monoamine oxidase (MAO) inhibitors or if you have taken MAO inhibitors in the last 14 days before treatment with **Codeine Contin**
- drugs used to treat serious mental or emotional disorders, such as schizophrenia
- antihistamines (for allergies)
- anti-emetics (for the prevention of vomiting)
- drugs used to treat muscle spasms and back pain
- some heart medications (such as beta blockers)
- anticoagulants (blood thinners)
- drugs used to treat migraines (e.g. triptans)
- St. John's Wort

How to take Codeine Contin:

Take **Codeine Contin** tablets every 12 hours with or without food with a full glass of water

Swallow whole. Do not cut, break, crush, chew or dissolve the tablet. This can be dangerous and can lead to death or seriously harm you. For three of the four dose strengths (100 mg, 150mg and 200mg), the tablet is scored and may be broken in half. **Do not cut, break, crush, chew or dissolve the half tablet.**

Usual Adult Starting Dose:

Your dose is tailored/personalized just for you. Be sure to follow your doctor's dosing instructions exactly. Do not increase or decrease your dose without consulting your doctor. Taking higher dose can lead to more side effects and a greater chance of overdose.

Review your pain regularly with your doctor to determine if you still need **Codeine Contin**. Be sure to use **Codeine Contin** only for the condition for which it was prescribed.

If your pain increases or you develop any side effect as a result of taking **Codeine Contin**, tell your doctor immediately.

Stopping your Medication

You should not stop taking **Codeine Contin** all at once if you have been taking it for more than a few days.

Your doctor will monitor and guide you on how to slowly stop taking **Codeine Contin**. You should do it slowly to avoid uncomfortable symptoms such as having:

- body aches
- diarrhea
- goosebumps
- loss of appetite
- nausea
- feeling nervous or restless
- runny nose
- sneezing
- tremors or shivering
- stomach cramps
- rapid heart rate (tachycardia)
- having trouble sleeping
- an unusual increase in sweating
- heart palpitations
- an unexplained fever
- weakness
- yawning

By reducing or stopping your opioid treatment, your body will become less used to opioids. If you start treatment again, you will need to start at the lowest dose. You may overdose if you restart at the last dose you took before you slowly stopped taking **Codeine Contin**.

Refilling your Prescription for Codeine Contin:

A new written prescription is required from your doctor each time you need more **Codeine Contin**. Therefore, it is important that you contact your doctor before your current supply runs out.

Only obtain prescriptions for this medicine from the doctor in charge of your treatment. Do not seek prescriptions from other doctors unless you switch to another doctor for your pain management.

Overdose:

If you think you have taken too much **Codeine Contin**, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Signs of overdose may include:

- unusually slow or weak breathing
- dizziness
- confusion
- extreme drowsiness

Missed Dose:

If you miss one dose, take it as soon as possible. However, if it is almost time for your next dose, then skip the missed dose. Do not take two doses at once. If you miss several doses in a row, talk to your doctor before restarting your medication.

What are possible side effects from using Codeine Contin?

These are not all the possible side effects you may feel when taking **Codeine Contin**. If you experience any side effects not listed here, contact your healthcare professional.

Side effects may include:

- Confusion
- Drowsiness
- Insomnia
- Dizziness
- Fainting
- Nausea, vomiting, or a poor appetite
- Dry mouth
- Headache
- Problems with vision
- Weakness, uncoordinated muscle movement
- Itching
- Light headedness
- Sweating
- Constipation
- Low sex drive, impotence (erectile dysfunction), infertility

Talk with your doctor or pharmacist about ways to prevent constipation when you start using **Codeine Contin**.

Serious side effects and what to do about them				
Symptom / effect		Talk to your healthcare professional		Stop taking drug and get immediate medical help
		Only if severe	In all cases	
RARE	Overdose: hallucinations, confusion, inability to walk normally, slow or weak breathing, extreme sleepiness, sedation, or dizziness, floppy muscles/low muscle tone, cold and clammy skin.			√
	Respiratory Depression: slow, shallow or weak breathing.			√
	Allergic Reaction: rash, hives, swelling of the face, lips, tongue or throat, difficulty swallowing or breathing			√
	Bowel Blockage (impaction): abdominal pain, severe constipation, nausea			√
	Withdrawal: nausea, vomiting, diarrhea, anxiety, shivering, cold and clammy skin, body aches, loss of appetite, sweating.		√	
	Fast, Slow or Irregular Heartbeat: heart palpitations.		√	
	Low Blood Pressure: dizziness, fainting, light-headedness.	√		
	Serotonin Syndrome: agitation or restlessness, loss of muscle control or muscle twitching, tremor, diarrhea			√

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

We encourage you to report serious or unexpected side effects to Health Canada. The information is used to check for new safety concerns about health products. As a consumer, your report contributes to the safe use of health products for everyone.

3 ways to report:

- Online at MedEffect: <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>
 - By calling 1-866-234-2345 (toll-free);
 - By completing a Consumer Side Effect Reporting Form and sending it by:
 - Fax to 1-866-678-6789 (toll-free), or
 - Mail to: Canada Vigilance Program
Health Canada, Postal Locator 1908C
Ottawa, ON
K1A 0K9
- Postage paid labels and the Consumer Side Effect Reporting Form are available at [MedEffect](https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html) (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>).

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

Storage:

- **Keep unused or expired Codeine Contin in a secure place to prevent theft, misuse or accidental exposure.**
- Store at room temperature (15° C- 30°C). Keep in a dry place.
- **Keep Codeine Contin under lock, out of sight and reach of children and pets.**
- **Never take medicine in front of small children as they will want to copy you. Accidental ingestion by a child is dangerous and may result in death. If a child accidentally takes Codeine Contin, get emergency help right away.**

Disposal:

Codeine Contin should never be thrown into household trash, where children and pets may find it. It should be returned to a pharmacy for proper disposal.

If you want more information about Codeine Contin:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this patient medication information by visiting the Health Canada website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website <http://www.purdue.ca>, or by calling 1-800-387-4501.

This leaflet was prepared by Purdue Pharma.

Last Revised: September 12, 2018

Codeine Contin[®] is a trademark of Purdue Pharma